Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

|

High$
Low$
Volume
Market Cap

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases
More  
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results
03/15/19
Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
12/03/18
Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
11/08/18
Investor Events
More  
There are currently no events scheduled.